Gelfoam slurry

Phase 2Biologic

UUniversity of Miami

Gelfoam slurry is one of 5 biologic programs targeting Pneumothorax. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumothoraxActive, not recruiting

PneumothoraxPhase 2

Active, not recruiting

Competition

Competitive Landscape

10 competitors in Pneumothorax

#DrugCompanyPhaseTrials

Minocin

Paracetamol

1 3

Platelet Rich Plasma

ZZagazig University

Phase 1

1 4

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

1 5

Gelfoam slurry

UUniversity of Miami

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumothorax1 trial

Gelfoam to Prevent Pneumothorax After Lung Biopsy

Withdrawn·UUniversity of Miami·Phase 2·NCT03669003

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gelfoam slurry. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gelfoam slurry compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gelfoam slurry. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Miami company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Miami

Gelfoam slurry

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumothorax1 trial

References

Drug Info

Quick Facts

Related News